Allergic rhinoconjunctivitis: pathophysiological mechanism and new therapeutic approach

Giorgio Ciprandi, Salvatore Leonardi, Anna Maria Zicari, Maria Angela Tosca, Gianluigi Marseglia

Research output: Contribution to journalArticlepeer-review


Allergic rhinoconjunctivitis (AR) is the most common IgE-mediated disease. A type2 immune response is involved in AR pathogenesis. Allergic inflammation is characterized by eosinophilic infiltrate and mediators release. AR treatment is usually based on medication prescription, including antihistamines and intranasal corticosteroids. However, medications may be prescribed for long periods and sometimes may be scarcely effective, thus aggressive strategy should be used. Therefore, complementary medicine is becoming attractive for patients at present. Nutraceuticals represent interesting therapeutic options in clinical practice. In this regard, a new compound has been designed containing Vitamin D3, Perilla extract, and quercetin.

Original languageEnglish
Pages (from-to)93-96
Number of pages4
JournalActa bio-medica : Atenei Parmensis
Issue number1
Publication statusPublished - Mar 19 2020

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Allergic rhinoconjunctivitis: pathophysiological mechanism and new therapeutic approach'. Together they form a unique fingerprint.

Cite this